JPWO2020132291A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020132291A5
JPWO2020132291A5 JP2021535665A JP2021535665A JPWO2020132291A5 JP WO2020132291 A5 JPWO2020132291 A5 JP WO2020132291A5 JP 2021535665 A JP2021535665 A JP 2021535665A JP 2021535665 A JP2021535665 A JP 2021535665A JP WO2020132291 A5 JPWO2020132291 A5 JP WO2020132291A5
Authority
JP
Japan
Prior art keywords
seq
set forth
recombinant protein
chain variable
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021535665A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022515152A5 (https=
JP2022515152A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/067563 external-priority patent/WO2020132291A1/en
Publication of JP2022515152A publication Critical patent/JP2022515152A/ja
Publication of JP2022515152A5 publication Critical patent/JP2022515152A5/ja
Publication of JPWO2020132291A5 publication Critical patent/JPWO2020132291A5/ja
Priority to JP2024192700A priority Critical patent/JP2025032075A/ja
Pending legal-status Critical Current

Links

JP2021535665A 2018-12-19 2019-12-19 Ｂａｆｆ－ｒ二重特異性ｔ細胞エンゲージャー抗体 Pending JP2022515152A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024192700A JP2025032075A (ja) 2018-12-19 2024-11-01 Ｂａｆｆ－ｒ二重特異性ｔ細胞エンゲージャー抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862782317P 2018-12-19 2018-12-19
US62/782,317 2018-12-19
PCT/US2019/067563 WO2020132291A1 (en) 2018-12-19 2019-12-19 Baff-r bispecific t-cell engager antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024192700A Division JP2025032075A (ja) 2018-12-19 2024-11-01 Ｂａｆｆ－ｒ二重特異性ｔ細胞エンゲージャー抗体

Publications (3)

Publication Number Publication Date
JP2022515152A JP2022515152A (ja) 2022-02-17
JP2022515152A5 JP2022515152A5 (https=) 2022-12-21
JPWO2020132291A5 true JPWO2020132291A5 (https=) 2022-12-21

Family

ID=71098268

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021535665A Pending JP2022515152A (ja) 2018-12-19 2019-12-19 Ｂａｆｆ－ｒ二重特異性ｔ細胞エンゲージャー抗体
JP2024192700A Pending JP2025032075A (ja) 2018-12-19 2024-11-01 Ｂａｆｆ－ｒ二重特異性ｔ細胞エンゲージャー抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024192700A Pending JP2025032075A (ja) 2018-12-19 2024-11-01 Ｂａｆｆ－ｒ二重特異性ｔ細胞エンゲージャー抗体

Country Status (8)

Country Link
US (2) US20200199232A1 (https=)
EP (1) EP3897720A4 (https=)
JP (2) JP2022515152A (https=)
KR (1) KR20210104816A (https=)
CN (2) CN113412124A (https=)
AU (1) AU2019404282A1 (https=)
CA (1) CA3123599A1 (https=)
WO (1) WO2020132291A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
CA3261672A1 (en) * 2022-07-19 2024-01-25 Novartis Ag TREATMENT OF AIHA WITH BAFF OR BAFF RECEPTOR INHIBITOR ANTIBODIES
WO2024074145A1 (zh) * 2022-10-08 2024-04-11 盛禾(中国)生物制药有限公司 一种结合baffr和cd3的双特异性抗体及其应用
AU2024227909A1 (en) * 2023-02-28 2025-08-14 Mayo Foundation For Medical Education And Research Molecules that bind to b-cell activating factor receptor polypeptides
WO2025221674A1 (en) * 2024-04-15 2025-10-23 Eli Lilly And Company Baffr x cd3 bispecific antibodies and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2216342B1 (en) * 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
RU2679124C2 (ru) * 2012-11-06 2019-02-06 Байер Фарма Акциенгезельшафт Препарат для биспецифических активаторов т-клеток (bite)
EP2948475A2 (en) * 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
AU2015295242B2 (en) * 2014-07-31 2020-10-22 Amgen Research (Munich) Gmbh Bispecific single chain antibody construct with enhanced tissue distribution
WO2016094873A2 (en) * 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
EP3778640A1 (en) * 2015-05-01 2021-02-17 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
EP3916018A1 (en) * 2015-06-16 2021-12-01 Genentech, Inc. Anti-cd3 antibodies and methods of use
US10072088B2 (en) * 2015-08-17 2018-09-11 Janssen Pharmaceutica, Nv Anti-BCMA antibodies and uses thereof
CN116063544A (zh) * 2016-02-03 2023-05-05 安进研发（慕尼黑）股份有限公司 Bcma和cd3双特异性t细胞接合抗体构建体
KR20250084978A (ko) * 2016-06-06 2025-06-11 시티 오브 호프 Baff-r 표적 키메라 항원 수용체-변형된 t 세포 및 그 용도
CN116041514A (zh) * 2016-06-06 2023-05-02 希望之城 Baff-r抗体及其用途
JP2019529499A (ja) * 2016-09-30 2019-10-17 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 組織指向性発現を用いた抗体ベースの遺伝子治療
KR20210129125A (ko) * 2019-02-20 2021-10-27 시티 오브 호프 Baff-r/cd19 표적화된 키메라 항원 수용체-변형된 t 세포 및 그의 용도

Similar Documents

Publication Publication Date Title
JP2024096688A5 (https=)
JP2025111463A5 (https=)
JP2021184721A5 (https=)
JP2020180158A5 (https=)
JP2023123726A5 (https=)
JP2023178323A5 (https=)
JP2021524267A5 (https=)
JP2023081303A5 (https=)
JP2021525546A5 (https=)
JPWO2020011964A5 (https=)
JP2021522162A5 (https=)
JP2009521909A5 (https=)
JP2020531438A5 (ja) Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質
JP2007532139A5 (https=)
JP2020522254A5 (https=)
RU2006115835A (ru) Человеческие антитела против человеческого 4-1вв (cd137)
JP2025032102A5 (https=)
JPWO2019204564A5 (https=)
JPWO2020132291A5 (https=)
JPWO2020011976A5 (https=)
JPWO2019166650A5 (https=)
JP2016529213A5 (https=)
JP2021524451A5 (https=)
JPWO2019152705A5 (https=)
JPWO2022094299A5 (https=)